GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Valuation Rank

NextCure (FRA:2US) Valuation Rank


View and export this data going back to 2019. Start your Free Trial

What is NextCure Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

NextCure Valuation Rank Related Terms

Thank you for viewing the detailed overview of NextCure's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NextCure Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NextCure Inc (FRA:2US) » Definitions » Valuation Rank
Comparable Companies
LVTX PVCT INAB MTEM PMN SIOX EFTR NLTX SLS LUMO OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
NXTC:USA
Address
9000 Virginia Manor Road, Suite 200, Beltsville, MD, USA, 20705
Website
https://www.nextcure.com
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.